HLS Therapeutics Inc experienced a notable decline today, with shares dropping 3.15% amid mixed financial signals.
HLS Therapeutics Inc (HLS.TO) saw its stock price decrease by 3.15% in the latest trading session, closing at CA$4.31. Despite recent announcements about revenue growth and new product launches, investor sentiment seems cautious, leading to today's downturn.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$132.29M
52W high
$5.76
52W low
$4.00
1W change
-3.72%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 77.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.33
+77.0% Upside
Current Price
C$4.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.5%
Annualized
90-Day Vol
22.5%
Annualized
Trend (90d)
-48.8%
Annualized drift
90d Mean
C$3.48
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.91 | C$3.53 โ C$4.32 |
| 60 trading days | C$3.69 | C$3.19 โ C$4.26 |
| 90 trading days | C$3.48 | C$2.92 โ C$4.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of today's decline in HLS Therapeutics' stock price, especially in light of its recent financial results and product developments.
HLS Therapeutics Inc down 3.15% today
With a market cap of CA$139 million, the stock's decline reflects broader investor concerns despite recent positive sales figures.
Bull case
The company reported a 2% increase in revenue year-over-year for Q1 2026, along with a significant 15% growth in Vascepa net sales. This could indicate a positive trajectory for future earnings.
Bear case
Even with some revenue growth, HLS Therapeutics has a negative profit margin of -18.46%, which raises concerns about its overall financial health and sustainability in a competitive market.
Recent Performance Overview
HLS Therapeutics Inc has been facing challenges in maintaining investor confidence, as shown by today's 3.15% drop in stock price. This decline comes despite a reported increase in revenue and product launches, suggesting that the market may be reacting to underlying financial concerns.
Financial Health and Market Sentiment
With a negative profit margin and a market cap of CA$139 million, HLS Therapeutics is navigating a complex landscape. Investors should weigh the recent revenue growth against the company's financial struggles, especially as they prepare for the upcoming Q1 2026 financial results conference call.
Looking Ahead
As HLS Therapeutics prepares to discuss its financial results on May 15, 2026, investors will be eager to hear more about the company's strategies to improve profitability and sustain growth. The upcoming conference could provide critical insights into the company's future direction.
Advertisement
